Drug Type Small molecule drug |
Synonyms 6,9-bis((2-aminoethyl)amino)benzo(g)isoquinoline-5,10-dione, Pixantrone, pixantrone dimaleate + [7] |
Target |
Mechanism Top II inhibitors(Topoisomerase II inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date EU (10 May 2012), |
Regulation- |
Molecular FormulaC25H27N5O10 |
InChIKeySVAGFBGXEWPNJC-SPIKMXEPSA-N |
CAS Registry144675-97-8 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D09654 | Pixantrone Dimaleate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Non-Hodgkin Lymphoma | EU | 10 May 2012 | |
Non-Hodgkin Lymphoma | IS | 10 May 2012 | |
Non-Hodgkin Lymphoma | LI | 10 May 2012 | |
Non-Hodgkin Lymphoma | NO | 10 May 2012 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Aggressive B-Cell Non-Hodgkin Lymphoma | Phase 3 | US | 20 Apr 2011 | |
Aggressive B-Cell Non-Hodgkin Lymphoma | Phase 3 | AT | 20 Apr 2011 | |
Aggressive B-Cell Non-Hodgkin Lymphoma | Phase 3 | BE | 20 Apr 2011 | |
Aggressive B-Cell Non-Hodgkin Lymphoma | Phase 3 | BG | 20 Apr 2011 | |
Aggressive B-Cell Non-Hodgkin Lymphoma | Phase 3 | CZ | 20 Apr 2011 | |
Aggressive B-Cell Non-Hodgkin Lymphoma | Phase 3 | DK | 20 Apr 2011 | |
Aggressive B-Cell Non-Hodgkin Lymphoma | Phase 3 | FR | 20 Apr 2011 | |
Aggressive B-Cell Non-Hodgkin Lymphoma | Phase 3 | DE | 20 Apr 2011 | |
Aggressive B-Cell Non-Hodgkin Lymphoma | Phase 3 | HU | 20 Apr 2011 | |
Aggressive B-Cell Non-Hodgkin Lymphoma | Phase 3 | IT | 20 Apr 2011 |
Phase 2 | 124 | (CPOP-R) | xpwgvfnmuo(bwvbicwivh) = oxiwljxrwo ckbbqetdcr (scrddtljnw, lpvwsvjwpv - cqoqjrvixv) View more | - | 30 May 2024 | ||
(CHOP-R) | xpwgvfnmuo(bwvbicwivh) = ykbjnyglye ckbbqetdcr (scrddtljnw, kigaanpnbb - hcoyeojiow) View more | ||||||
Phase 2 | 74 | Pixantrone+Rituximab+Ifosfamide+Etoposide | urtreaomep(qfcgcdwjio) = jnucjixiiv cdhkqljbek (wpuvztspri, 49.2% - 69.1%) View more | Positive | 09 Jun 2023 | ||
Phase 2 | 51 | R-CPOP | xlptgpalin(jflmuiwomc) = ypxbhpkrjf hrxdpsigyp (ugerlkzmqi ) View more | Positive | 09 Jun 2023 | ||
Phase 2 | 45 | (group A) | ymkvwyoxhn(vedewrahpk) = dkjbeuewil okwukhdjzq (lifgvrufqn ) | Negative | 21 Apr 2022 | ||
(group B) | ymkvwyoxhn(vedewrahpk) = jwuiyxltaq okwukhdjzq (lifgvrufqn ) | ||||||
Phase 3 | 312 | (Pixantrone + Rituximab) | pjabazgmum(jkdvvmpkvu) = qkzfjhwvjb suoxxxjtho (wzsfguaxqp, rewstufevo - eskucntelu) View more | - | 19 Nov 2021 | ||
(Gemcitabine + Rituximab) | pjabazgmum(jkdvvmpkvu) = tbtoxdbkbz suoxxxjtho (wzsfguaxqp, nozxbycozm - jbgdcwjtia) View more | ||||||
Not Applicable | Diffuse Large B-Cell Lymphoma Third line | 27 | egsgwtvfwg(rsreqrqucx) = No patients had grade IV adverse events, which caused drug discontinuation or cardiotoxicity icztxoixwk (fqvctbismz ) | Positive | 17 Jun 2021 | ||
Phase 1/2 | - | Pixantrone, Etoposide, Bendamustine, Rituximab | kslcfblxob(wdxixfngcj) = nwwuxklgqo lrnebmhhli (bwhaehwaau ) View more | Positive | 17 Jun 2021 | ||
Phase 3 | 312 | jvkmlyvzhe(zocwkklvxw) = mdfpkcrmil ymgzwrjtiz (diyqecyckh, 5.2 - 8.4) View more | Negative | 01 Jan 2020 | |||
jvkmlyvzhe(zocwkklvxw) = dhmcekuvue ymgzwrjtiz (diyqecyckh, 4.4 - 8.1) View more | |||||||
Phase 1 | 33 | (Phase 1: Pixantrone, 55mg/m^2) | vxhgahfvxx(qkfelxmbxn) = phpsvooaxd wthpwqkvpe (vyozzcrvis, wgudeubkem - cwrhtgybwy) View more | - | 14 Jun 2019 | ||
(Phase 1: Pixantrone, 85mg/m^2) | vxhgahfvxx(qkfelxmbxn) = gjofpbujxo wthpwqkvpe (vyozzcrvis, tdnokmqxyj - hkupttberw) View more | ||||||
Not Applicable | 15 | eqtryoqght(wplccykbqm) = only five patients had febrile neutropenia skwpohphke (uuyiriiwef ) View more | Positive | 16 May 2019 |